Recursion announces pricing of $200 million public offering of Class A common stock - Utah Business https://buff.ly/3xOFJHE
This Week in Digital Health’s Post
More Relevant Posts
-
Scilex Holding Company has retained our firm, alongside Christian Attar Law, to investigate potential naked short selling and various market manipulation of its stock price. As mentioned on Yahoo! Finance, Scilex believes it has been targeted by stock manipulators to drive the market price of its securities downward. Our firms have been retained to investigate potential naked short selling activities, short positions, lending program activities and constitute market manipulation of its restricted shares of common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. that breach the restrictions on transfer which are currently in place through March 31, 2024 on these Restricted Dividend Shares. Learn more: https://lnkd.in/efEKi7Zt #MarketManipulation #ShortSelling #MarketManipulationInvestigation
To view or add a comment, sign in
-
Join my Goodwin colleagues @Caroline Bullerjahn, @Tucker DeVoe and @Justin Ward, and outside speaker @Frank Schneider from Cornerstone Research, as they dive into the key updates and recent trends concerning securities class actions filed against publicly traded life sciences companies. Gain valuable perspectives on recent impactful decisions, potential implications of those decisions, and practical steps you can take to make informed choices for your business. #GoodwinLaw #SecuritiesLitigation #LifeSciences #2024Trends Register here: https://lnkd.in/gK3DX5hy
2023-2024 Key Trends and Updates: Securities Litigation Against Life Sciences Companies | Goodwin | Event
goodwinlaw.com
To view or add a comment, sign in
-
Thoughts on this? >> Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #pharma #biotech #productmarketing
Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows
https://endpts.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech
Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows
https://endpts.com
To view or add a comment, sign in
-
Buy & Sell Signals How the price action of Avanos Medical Inc. ($AVNS) is used to our Advantage: Stock Traders Daily has produced this trading report using a proprietary method. This methodology [...] Look at the Charts
How the price action of Avanos Medical Inc. ($AVNS) is used to our Advantage
news.stocktradersdaily.com
To view or add a comment, sign in
-
And here's even more current analysis from Timothy Seymour on the #cannabis sector; part of the updates he provides on a weekly basis. $CNBS Listen now: https://hubs.li/Q02BzM7s0 #thematics #etfs
The Cannabis Recap - June 11, 2024
blog.amplifyetfs.com
To view or add a comment, sign in
-
#OPGN - 500 Gain In Premarket Session Heres Why Precision Medicine OpGen Stock Is Soaring Benzinga OpGen Inc (NASDAQ: OPGN) stock is trading higher following two SEC filings from the precision medicine company. The company has rece... October 12, 2023 at 12:36PM #StockMarket #MWN
OPGN - 500% Gain In Premarket Session - Here's Why Precision Medicine OpGen Stock Is
marketwirenews.com
To view or add a comment, sign in
-
Following up on an article I shared recently on this topic, my Goodwin colleagues, Caroline Bullerjahn, Tucker DeVoe and Justin Ward will be hosting a webinar to discuss in more detail key 2023-2024 updates and trends in securities class action litigations filed against life sciences companies. To tune in, click on the link below. One hour CLE credit pending in California, New York, New Jersey, and/or Pennsylvania. #goodwinlaw #legalupdate #lifesciences #litigation
2023-2024 Key Trends and Updates: Securities Litigation Against Life Sciences Companies | Goodwin | Event
goodwinlaw.com
To view or add a comment, sign in
-
IPO grants Daiichi patent for Edoxaban orally disintegrating composition. Inventive step & S.3(e) traversed. IN201917022577, family to EP3549585
To view or add a comment, sign in
24,893 followers